Paolo Tarantino @PTarantinoMD
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs & good music. Boston, MA Joined January 2018-
Tweets10K
-
Followers22K
-
Following532
-
Likes40K
DB06 TDXD compared to chemo of choice showed positive PFS in MBC HR+ HER-2 low or ultralow post 1-2 line of endocrine therapy (Chemo-Naive Patients) Sooo excited to see the Kaplan–Meier curves details #ASCO2024
DB06 TDXD compared to chemo of choice showed positive PFS in MBC HR+ HER-2 low or ultralow post 1-2 line of endocrine therapy (Chemo-Naive Patients) Sooo excited to see the Kaplan–Meier curves details #ASCO2024
T-DXd has shown remarkable activity for treating HER2-positive and HER2-low breast cancers. However, it may soon expand its reach, and become a treatment option even for HER2-0 tumors. Here’s the 10 reasons why:
Refresher for the current & upcoming definitions of HER2 in breast oncology: Table 1 from the @myESMO consensus on HER2-low matches each pattern of HER2 IHC expression with the conclusion by the ASCO/CAP guidelines and by the Consensus group. 👉 annalsofoncology.org/article/S0923-…
Such an important question addressed in the Alliance A011502 study looking at adjuvant aspirin in breast cancer found no benefit. Wonderful work by Wendy Chen and the Alliance team! @DFCI_BreastOnc
Such an important question addressed in the Alliance A011502 study looking at adjuvant aspirin in breast cancer found no benefit. Wonderful work by Wendy Chen and the Alliance team! @DFCI_BreastOnc
Answer: Only <5% of the weight of an ADC is determined by the payload. Examples: - T-DM1: MW 145,000 Da, of which ≈2500 Da related to the payload (738 Da X 3.5 [DAR]) - T-DXd: MW 158,000 Da, of which ≈4000 Da related to the payload (493 Da X 8 [DAR]) @EladSharonMD
Answer: Only <5% of the weight of an ADC is determined by the payload. Examples: - T-DM1: MW 145,000 Da, of which ≈2500 Da related to the payload (738 Da X 3.5 [DAR]) - T-DXd: MW 158,000 Da, of which ≈4000 Da related to the payload (493 Da X 8 [DAR]) @EladSharonMD
@PTarantinoMD Reason 11: free payload exposure. pubmed.ncbi.nlm.nih.gov/34895651/
10 reasons why T-DXd can be effective for treating HER2-0 breast cancer from 1.5 yrs ago All still valid 🧵👇
10 reasons why T-DXd can be effective for treating HER2-0 breast cancer from 1.5 yrs ago All still valid 🧵👇
@DrChoueiri @DFCI_BreastOnc @DrHBurstein @PTarantinoMD @stolaney1 @elmayermd @BreastCancerNow @SusanGKomen @AnnPartridgeMD @antgiorda @Otto_DFCI Beyond the press release: The question here is to know how much better T-Dx is in terms os PFS. The magnitude of benefit should’ve to be clearly significative since a clinical point of view to defeat capecitabine (good, cheap, easy, per os, and with better tolerability.
Excited to share that our article on the impact of neoadjuvant #pembro in early #TNBC was just published in the @OncJournal! @jmortimer @hmcarthur Younger patients and those who completed 8 cycles of neoadjuvant pembro were more like to achieve pCR. academic.oup.com/oncolo/advance…
Please include some patients with “marker-negative” tumors in early #drugdevelopment. Drugs often have more targets than we know, & sometimes the first target we find isn’t even the best one. It’s a lot more resource-intensive to go back & figure this out. #OncTwitter
In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC Press release out from DESTINY-Breast06 Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker
In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC Press release out from DESTINY-Breast06 Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker
Well, the @DanaFarber_GU is hiring again: Apply at: nejmcareercenter.org/job/760635/gen…
Here's the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 22nd-28th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
Ever evolving HER2 low. Hoping this will find its way to ASCO!
Ever evolving HER2 low. Hoping this will find its way to ASCO!
HER2 is about to change again. In DESTINY-Breast06, T-DXd significantly improved PFS in chemo-naive patients with HER2-low and HER2-#ultralow MBC. OS immature. Presented at ASCO? Press Release: astrazeneca.com/media-centre/p… Navigating HER2-low: aacrjournals.org/cancerdiscover…
HER2 is about to change again. In DESTINY-Breast06, T-DXd significantly improved PFS in chemo-naive patients with HER2-low and HER2-#ultralow MBC. OS immature. Presented at ASCO? Press Release: astrazeneca.com/media-centre/p… Navigating HER2-low: aacrjournals.org/cancerdiscover… https://t.co/XHzm6HdP0r
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - businesswire.com/news/home/2024…
Here we go again?? #HER2 is about to change again. Seems like every month is a new knowledge about #HERlow #HER2ultralow 👏💪 @PTarantinoMD @SDS_Optic @inPROBE_
Here we go again?? #HER2 is about to change again. Seems like every month is a new knowledge about #HERlow #HER2ultralow 👏💪 @PTarantinoMD @SDS_Optic @inPROBE_
Vivek Subbiah, MD @VivekSubbiah
34K Followers 2K Following Chief, Early-Phase Drug Development|@SarahCannonDocs #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
Matteo Lambertini, MD.. @matteolambe
14K Followers 453 Following Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Chair of @myESMO YOC. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.
Toni Choueiri, MD @DrChoueiri
36K Followers 480 Following Senior Executive & Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; 2021 Giants of Cancer Award ⚽ lover; 🚲@PanMass, seen on @msnbc @cnn @TODAYshow @GMA
Erika Hamilton, MD @ErikaHamilton9
15K Followers 3K Following Med Onc, Director of Breast Cancer Research Program @ Sarah Cannon Research Institute #bcsm #WomenInMedicine Wife, Mom to 2 girls, tweets are mine.
Aleix Prat #Precision.. @prat_aleix
13K Followers 699 Following Head Oncology @hospitalclinic, CoFounder @RevealGenomics, TranslGenomics @IDIBAPS, Prof @UniBarcelona, Team @IOBoncologia, COI https://t.co/HZFOVJKZcd
Rebecca Shatsky, MD @Dr_RShatsky
13K Followers 2K Following Breast cancer medical oncologist @UCSD specializing in young patients, TNBC, Lobular, MBC, and precision/personalized oncology. Views are my own.
Hope Rugo @hoperugo
9K Followers 546 Following
SABCS @SABCSSanAntonio
12K Followers 755 Following An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer
Stephanie Graff, MD, .. @DrSGraff
19K Followers 4K Following Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine
Sara Tolaney @stolaney1
10K Followers 620 Following Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls
Stephen V Liu, MD @StephenVLiu
24K Followers 3K Following Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #DCLung24 #TexasLung24 #HereWeGo
Harold J. Burstein, M.. @DrHBurstein
12K Followers 535 Following Breast cancer specialist and professor @DanaFarber Cancer Institute and @HarvardMed. Tweets are my own and not medical advice. COI disclosure: no COI.
Oncology Brothers @OncBrothers
12K Followers 408 Following Practice changing 🗣 by community oncologists: Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews & not medical advice.COI https://t.co/cJOjp0RvQE
ESMO - Eur. Oncology @myESMO
75K Followers 874 Following The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
Dana-Farber’s Breas.. @DFCI_BreastOnc
4K Followers 334 Following Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425
OncLive.com @OncLive
44K Followers 2K Following Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Sumanta K. Pal, MD, F.. @montypal
19K Followers 4K Following @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail [email protected].
Dr Sarah Sammons @drsarahsam
4K Followers 1K Following Breast Medical Oncologist @dfci_breastonc. Harvard Medical School. Associate Director EMBRACE MBC Program. Tweets are NOT medical advice.
Annals of Oncology @Annals_Oncology
47K Followers 521 Following Medical oncology journal with a specific interest on targeted agents, immune therapies, personalised medicine, molecular pathology, bioinformatics, and more.
Myriam Chalabi @MyriamChalabi
6K Followers 496 Following Medical Oncologist, GI cancers @nki_nl neoadjuvant #immunotherapy #cancerresearch. Opinions my own
ana laura @analauracarlini
110 Followers 388 Following
Tess K @TessK113325
2 Followers 62 Following
yoyokoko @kciwn1
16 Followers 36 Following
tess research @research_tess
2K Followers 5K Following TESS Research is a non-profit scientific publishing organization which publishes high quality, peer-reviewed journals #Health #Medical #Economics #Webinar
Sadab Jaowad @JaowadSadab
11 Followers 284 Following
Yuval Cohen @CEOCorbus
2K Followers 901 Following I'm the CEO of @CorbusPharma ($CRBP). I'm passionate about inflammatory/fibrotic/metabolic diseases and cancer. These opinions are my own.
FernandoRod @PsiconautaFer
42 Followers 352 Following
Tidiane Diallo @TidianeDia95937
5 Followers 78 Following
Tracey Cook @TraceyTLC333
711 Followers 3K Following Mum who fights for her kids. ASD, Leukaemia, Hypertrophic Cardiomyopathy, Epileptic Encephalopathy, ESES, Graves’ disease +. Loves all Animals, especially Dogs.
Pabu Ram Jakhar @pabu_ram861928
5 Followers 277 Following
Tom Okoth @aihealthtom
0 Followers 3 Following Strategic Planner at the Intersection of AI and Healthcare Innovation.
David Thompson @dthmpsnhealth
0 Followers 3 Following Champion des innovations en santé mondiale et des politiques publiques.
Tiziana Latiano @latiano_titty
22 Followers 111 Following
Santosh Kumar Mandal @Santosh07Mandal
10 Followers 219 Following
Shreya Stephen @stephen_shreya
1 Followers 27 Following
Ryan Lu @RyanLu_CRP
198 Followers 605 Following Polymer Enthusiast| NanoMed| PhD candidate in @UMassThaiGroup @UMassChemistry| Alum Polymer Engineer @DuPont_News
Julieti Buss @julietihuchbuss
0 Followers 33 Following
Gilmar dos Santos @x_xnachax_x
177 Followers 3K Following
淸水 珉奭 (김일.. @riversay
15 Followers 51 Following 범띠, 마지막 학력고사, 엑스포학번, 청성의 용사, 수의사, 정부출현연구소, 대기업, 오너기업, 벤처기업, Life is So Good ~ https://t.co/YrGgAmVo6y
Xiaoqi(Kevin) LI @kevinmartinlee
219 Followers 710 Following PhD@unmc|T-cell therapy|PDAC|Solid Tumor|Glycosylation|Resistance|Open to Wrok|Twitter is my own|RT≠E
Youly Kirsch @YoulyKirsc52167
0 Followers 12 Following
Yousef Salama @salamay840
4 Followers 211 Following Co-founder @ Repogen. Stem Cells. AI hospital. healthcare AI. Cancer Genomics. software. Aging. MedTech. Omics. Regenerative medicine
Karola Reyes Restrepo @KarolaRent28603
333 Followers 3K Following
Cara Gunning @gunning_cara
30 Followers 87 Following Meath native | Living in Cork | Mom of 3 ❤️ Oncology | Daiichi-Sankyo | Views my own
Kannouche Lab @KannoucheLab
79 Followers 107 Following Our lab at Gustave Roussy Institute studies DNA replication and error-prone mechanisms of repair leading to cancers and drug resistance.
Steve Vee @Niter1cbs
297 Followers 3K Following
Adriana Borello @adrianaborello7
0 Followers 3 Following
O&AI: The ChatGPT Oph.. @OphthalmologyAI
12K Followers 4K Following ChatGPT for ophthalmologists, researchers, doctors from other specialties who need an ophthalmological opinion, residents in ophthalmology and medical students.
Dr Nick Manning-Cork @NicholasMCork
1K Followers 3K Following Medical Oncology SpR @royalmarsdenNHS | Prev. @Bupa @CQCProf @GMCuk @NHSEngland @Cambridge_Uni | Healthcare Innovation, Improvement, & Sustainability #VBHC
Michael Stalteri @_mstalteri
465 Followers 587 Following Dana-Farber Cancer Institute, Breast Oncology | GWU MHA ‘24 | Union College (NY) ‘19
Gloria Mittica @GloriaMittica
1 Followers 11 Following
DocSurgy @DocSurgy
51 Followers 147 Following
Prarthna Shah @prarthna_shah
0 Followers 2 Following
Daniella Audi Blotta @DABlotta
0 Followers 7 Following
Phelipe Siani @PhelipeSiani000
116 Followers 2K Following
Charles Gordon @princetongb
4K Followers 1K Following We cannot direct the wind, but we can adjust the sails... Family Office. Founder Princeton Biomedical Consul. LLC.
Diana Viettri @Diana59241559
34 Followers 104 Following
Not MR Beast “Just .. @DrXRN119
14 Followers 126 Following Doctor of Nursing- Acknowledging RNs around the world. all opinions are mine
박동영 @wgPw9gtcR6ljiBR
1 Followers 15 Following
Jack Hall @Hall8Jack
1K Followers 3K Following Biotech, Commodities, etc. A like is not necessarily a like.
Amy Brown @ByAmyBrown
4K Followers 528 Following Freelance writer on the business of drug development, and all things pharma and biotech. DM or email at [email protected].
LFC @goldencaskcap
6K Followers 702 Following Mostly lurking unless something exciting happens. DMs open. Typos and views all my own.
Vivek Subbiah, MD @VivekSubbiah
34K Followers 2K Following Chief, Early-Phase Drug Development|@SarahCannonDocs #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
Matteo Lambertini, MD.. @matteolambe
14K Followers 453 Following Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Chair of @myESMO YOC. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.
Toni Choueiri, MD @DrChoueiri
36K Followers 480 Following Senior Executive & Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; 2021 Giants of Cancer Award ⚽ lover; 🚲@PanMass, seen on @msnbc @cnn @TODAYshow @GMA
Erika Hamilton, MD @ErikaHamilton9
15K Followers 3K Following Med Onc, Director of Breast Cancer Research Program @ Sarah Cannon Research Institute #bcsm #WomenInMedicine Wife, Mom to 2 girls, tweets are mine.
Aleix Prat #Precision.. @prat_aleix
13K Followers 699 Following Head Oncology @hospitalclinic, CoFounder @RevealGenomics, TranslGenomics @IDIBAPS, Prof @UniBarcelona, Team @IOBoncologia, COI https://t.co/HZFOVJKZcd
Rebecca Shatsky, MD @Dr_RShatsky
13K Followers 2K Following Breast cancer medical oncologist @UCSD specializing in young patients, TNBC, Lobular, MBC, and precision/personalized oncology. Views are my own.
Hope Rugo @hoperugo
9K Followers 546 Following
SABCS @SABCSSanAntonio
12K Followers 755 Following An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer
Stephanie Graff, MD, .. @DrSGraff
19K Followers 4K Following Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine
Sara Tolaney @stolaney1
10K Followers 620 Following Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls
Stephen V Liu, MD @StephenVLiu
24K Followers 3K Following Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #DCLung24 #TexasLung24 #HereWeGo
Harold J. Burstein, M.. @DrHBurstein
12K Followers 535 Following Breast cancer specialist and professor @DanaFarber Cancer Institute and @HarvardMed. Tweets are my own and not medical advice. COI disclosure: no COI.
FabriceAndre @FAndreMD
14K Followers 519 Following Head of Research Division of @GustaveRoussy , @myesmo President Elect
Oncology Brothers @OncBrothers
12K Followers 408 Following Practice changing 🗣 by community oncologists: Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews & not medical advice.COI https://t.co/cJOjp0RvQE
ESMO - Eur. Oncology @myESMO
75K Followers 874 Following The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
Dana-Farber’s Breas.. @DFCI_BreastOnc
4K Followers 334 Following Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425
OncLive.com @OncLive
44K Followers 2K Following Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Sumanta K. Pal, MD, F.. @montypal
19K Followers 4K Following @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail [email protected].
Dr Sarah Sammons @drsarahsam
4K Followers 1K Following Breast Medical Oncologist @dfci_breastonc. Harvard Medical School. Associate Director EMBRACE MBC Program. Tweets are NOT medical advice.
Annals of Oncology @Annals_Oncology
47K Followers 521 Following Medical oncology journal with a specific interest on targeted agents, immune therapies, personalised medicine, molecular pathology, bioinformatics, and more.
Giacomo Montagna MD M.. @MontagnaGiacomo
20 Followers 70 Following Breast Surgery at @MSKCancerCenter
Markus Eckstein @Markuseckstein3
1K Followers 2K Following #Pathologist #Physician Scientist @UniFAU University Hospital Erlangen, Germany #pathology #biomarker_research - My opinions are my own
Wendy Woodward MDPhD @IBCradiation
4K Followers 747 Following Radiation Oncology Inflammatory Breast Cancer Specialist and Scientist at MD Anderson Cancer Center. Tweets my own. @[email protected]
Fernanda Mosele @FerMosele
265 Followers 295 Following Clinical Oncologist, Breast cancer, Translational research @gustaveroussy
#FlorezLab @Florez_Lab
1K Followers 428 Following We are a Social Justice, Medical Education & Cancer Health Disparities Lab @DanaFarber - Florez Lab members are agents of change #FlorezLab IG:@florezlab
Guru P. Sonpavde, MD @sonpavde
4K Followers 197 Following Phase I+GU Oncology Director @AdventHealthCFL #Cancer Institute, Prof. @ucf Orlando, #Florida, #ASCO, #ESMO, #AACR, Following/Retweet ≠ endorsement, Views mine
Fabrice Barlesi @barlesi
3K Followers 487 Following CEO Gustave Roussy Cancer Campus Paris Saclay University Thoracic oncologist Cofounder Marseille Immunopole Coordinator #ThePioneeRproject Tweets are my own
Jacob Plieth @JacobPlieth
26K Followers 285 Following Journalist @ ApexOnco. The Wolverine Of Biotech / Mr ASH. Once had a blue tick. Interested in: oncology. Not interested in: what stock you bought today.
Dr. Dowdy Jackson @DrDowdyJackson
120 Followers 224 Following In the biotech and pharmaceutical industry for 25 years. Oncology drug development. Developing ADCs, biologics and small molecules from preclinical, IND and BLA
Pavlos Msaouel @PavlosMsaouel
3K Followers 1K Following Physician-Scientist, Oncologist, PI #MsaouelLab @MDAndersonNews | Tweets=my views | #kidneycancer #RenalMedullaryCarcinoma #endRMC #rarecancers
Federica Dieni @federicadieni
9K Followers 720 Following Deputata XVII e XVIII legislatura, già VicePresidente COPASIR. Mamma di Alessandro e Ludovica. Avvocato
MEDSIR @wearemedsir
1K Followers 1K Following Bring your idea to life💡Creating successful IITs & optimal drug development📊Medica Scientia Innovation Research🇪🇸🇺🇸https://t.co/TnOtdKHgxy…
CA: A Cancer Journal .. @CACancerJournal
10K Followers 3K Following As the flagship journal of the American Cancer Society, CA publishes the latest cancer statistics, ACS guidelines, and reviews on the current state of cancer.
Fotios Loupakis @fotiosloupakis
421 Followers 414 Following
Roberto Leon-Ferre @rleonferre
1K Followers 772 Following Breast Medical Oncologist - @MayoClinic. Focus on #TNBC and #immunoonc. Opinions are mine, not my employer’s. Orgullosamente ecuatoriano 🇪🇨
Sarah Waliany, MD, MS @SWaliany
968 Followers 876 Following Heme/Onc Fellow @DanaFarber/@MGHCancerCenter | Former Chief Res @StanfordMedRes | #ThoracicOnc #CardioOnc | Specialty Content Assistant Editor #JACCCardioOnc
Christina Curtis @cncurtis
3K Followers 1K Following Prof @ Stanford, Precision Oncology & Computational Biology
The Random Recruiter @randomrecruiter
26K Followers 969 Following Headhunter for Tech Pros. Billed $18.5M in profit & with ~700 placements at various F500s. The intersection of recruiting, job search, and careers.
Gevorg Tamamyan @GevTamamyan
2K Followers 3K Following Professor and Chair of Ped. Oncology and Hematolgy at YSMU, Head of @pcbdca, @poem_group President-Elect, Editor-in-chief of @oncodaily
DAVA Oncology @DAVAOnc
1K Followers 2K Following DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
Tennis TV @TennisTV
649K Followers 846 Following The best seat in tennis 🎾 Official streams: https://t.co/qhEoY7DtTv📱Get help: https://t.co/G6sWebIvYv 🤖 Buy merch: https://t.co/MvWFr5CDZF 👕
Madeleine Armstrong @ByMadeleineA
7K Followers 1K Following Senior reporter at @ApexOnco; cat lover; Croydon Harrier
Chiara Cremolini @ChiaraCrem1
1K Followers 78 Following Oncologa, ricercatrice, mamma di due mostri, appassionata di patate fritte e coca cola
Corriere della Sera @Corriere
2.8M Followers 240 Following L'informazione in 280 caratteri, 24 ore su 24. Siamo anche su Instagram e su Tik Tok @corriere
Giorgia Meloni @GiorgiaMeloni
2.3M Followers 248 Following Presidente del Consiglio dei Ministri della Repubblica Italiana
nature @Nature
2.6M Followers 4K Following Research, News, and Commentary from Nature, the international journal of science. For daily science news, get Nature Briefing: https://t.co/wGmQlQ8a4D
shimoi @shimoi_oncology
571 Followers 733 Following I am a medical oncologist. My areas of expertise are breast cancer, sarcoma, gynecologic cancer, urologic cancer, and rare cancers.
Shigehira Saji @shigehira
1K Followers 379 Following 福島県立医科大学 腫瘍内科学講座 主任教授 Fukushima Medical University, Prof. of Department of Medical Oncology
Juliana Beal, MD @JulianaRBeal
323 Followers 282 Following Medical oncologist at Hospital Israelita Albert Einstein interested in breast cancer, tumor agnostic developments and precision oncology
Josep Tabernero @TaberneroJosep
5K Followers 154 Following
Giuseppe Procopio @g_procopio_
170 Followers 170 Following Medical Oncologist focused on #GU cancers @IstTumori @meeturoIT @ficog
高野 利実 @ToshimiHBM
2K Followers 467 Following がん研有明病院の腫瘍内科医。「人間性に基づく医療(HBM)」をモットーに、乳がんの薬物療法や、患者さんを支える活動に取り組んでいます。腫瘍内科医の育成、新治療開発、サバイバーシップケア、がん教育、AYA世代がんのケアに力を入れています。ヨミドクター連載中で、「#気持ちがラクになるがんとの向き合い方」等の著書があります。
haruru kotani @HaluluKotani
6 Followers 59 Following
Kazuki Nozawa @kazuki_nozawa
992 Followers 476 Following Medical oncologist. Interested in breast oncology, ADCs, novel agent & jazz, coffee. 腫瘍内科医/乳がん情報チャンネル「BC tube」 @BC_tube
Simona Cristea @simocristea
7K Followers 496 Following Head of Data Science at Hale Center for Pancreatic Cancer | Group leader @DanaFarber @Harvard | We ❤️ genomics, evolution & LLMs | PhD @eth | 🇷🇴🇸🇪🇨🇭🇺🇸
Paigambar Raj @PgambarRaj
3K Followers 914 Following Breast Medical Oncologist @UNC_Lineberger Prior @JCO_ASCO editorial fellow. Views are my own.
Elad Sharon @EladSharonMD
3K Followers 4K Following #MedicalOncologist @DanaFarber tweeting on #immunotherapy, #drugdevelopment, #irAEs & #HealthEcon. Formerly @theNCI & #CancerMoonshot Adult ImmunoTx Co-Chair
Nature Reviews Cancer @NatureRevCancer
70K Followers 1K Following Nature Reviews Cancer is a monthly review journal for all researchers working on cancer. We, the editors, highlight the most exciting topics in cancer research.
Niklas Klümper @niklas_kluemper
1K Followers 3K Following Uro-Oncologist, Interested in precision oncology for ADC! NECTIN4 in met.UC? 🎯 Clinician Scientist and PI @IEO_HolzelLab @UniklinikBonn Tweets are my own
ESMO Open @ESMO_Open
5K Followers 419 Following The Open Access journal of @myESMO dedicated to oncology research
Lizzy Smyth @LizzySmyth1
3K Followers 2K Following Medical Oncologist. Cancer Researcher. 🇮🇪 in 🇬🇧 💙 🏳️🌈 #GastricCancer #OesophagealCancer @OxfordCancer #ESMO #EORTC
Elisa @ElisaFontana83
321 Followers 497 Following Ex-footballer retired for a better career in Medical Oncology/Translational Science/GI Oncology/Clinical Trials Sarah Cannon Research Institute UK
Diogo Martins Branco @DMBranco
669 Followers 642 Following #medonc MD 🇵🇹 & #pallonc MSc 🇬🇧 | @myESMO Scientific&Medical Division Fellow 🇨🇭 | #research #education #policy | Views are own 🎾
Adriano Aguzzi @AdrianoAguzzi
21K Followers 1K Following Physician, Prof of Neuropathology, mountain biker, prion researcher, https://t.co/p2LFL67xFj founder, Editor of @SwissMedWkly. Posts are orthogonal to my employer's.
Cecilia Sala @ceciliasala
94K Followers 5K Following Giornalista @Chora_Media e @ilfoglio_it. Faccio un podcast che si chiama "Stories" e racconta una storia dal mondo ogni giorno. In libreria con "L'incendio"
Jonathan Spicer MD Ph.. @DoctorJSpicer
4K Followers 1K Following Medical Director of the McGill Thoracic Oncology Program; Chest surgeon; Neutrophil biologist; Cancer immunologist; Aspiring farmer
Due laboratorini li abbiamo?
HR pos disease is rarely completely her2 0. There’s usually some her2 expression. Therefore results from this trial likely mean that we can use tdxd for all HR pos breast cancer. In TNBC things can be different since most of her2 0 tnbc has no her2 expression.
.@VKaklamani and @dradityabardia discussed the Phase III Destiny-Breast06 trial, in which TDXd demonstrated improvement in PFS in patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer. Watch now on SABCS Snippets: bit.ly/3JHpw9q @UTHealthSAMDA
Such an important question addressed in the Alliance A011502 study looking at adjuvant aspirin in breast cancer found no benefit. Wonderful work by Wendy Chen and the Alliance team! @DFCI_BreastOnc
💊Adjuvant Aspirin in Breast Cancer The Alliance A011502 randomized phase 3 trial @JAMA_current ❌Negative study, lack of benefit for invasive DFS and OS ➡️3020 participants ➡️high-risk nonmetastatic breast cancer ➡️Aspirin vs placebo ➡️By median follow-up of 33.8 months,…
AZ reports DESTINYbreast06 trial which is first line study of TDXD vs chemo in her2 low or ultra low (i.e. 0) tumors. So essentially drug works irrespective of Her2 status and “HER2 low” is a thing of the past astrazeneca.com/media-centre/p…
Incredibly grateful to @ILCAnews - the perfect platform to disseminate your research on liver cancer !
Seize this opportunity to showcase your work and connect with other liver cancer specialists as passionate as you. Learn more: ilcalive.org/annual-confere…
A great thread by @PTarantinoMD of why using HER2 IHC testing to select patients for #tdxd may not be necessary. Awaiting the presentation/publication of DB-06! #bcsm #educatepatients #MedTwitter #MedX astrazeneca.com/media-centre/p…
T-DXd has shown remarkable activity for treating HER2-positive and HER2-low breast cancers. However, it may soon expand its reach, and become a treatment option even for HER2-0 tumors. Here’s the 10 reasons why:
DB06 TDXD compared to chemo of choice showed positive PFS in MBC HR+ HER-2 low or ultralow post 1-2 line of endocrine therapy (Chemo-Naive Patients) Sooo excited to see the Kaplan–Meier curves details #ASCO2024
HER2 is about to change again. In DESTINY-Breast06, T-DXd significantly improved PFS in chemo-naive patients with HER2-low and HER2-#ultralow MBC. OS immature. Presented at ASCO? Press Release: astrazeneca.com/media-centre/p… Navigating HER2-low: aacrjournals.org/cancerdiscover…
@PTarantinoMD Reason 11: free payload exposure. pubmed.ncbi.nlm.nih.gov/34895651/
@DrChoueiri @DFCI_BreastOnc @DrHBurstein @PTarantinoMD @stolaney1 @elmayermd @BreastCancerNow @SusanGKomen @AnnPartridgeMD @antgiorda @Otto_DFCI Beyond the press release: The question here is to know how much better T-Dx is in terms os PFS. The magnitude of benefit should’ve to be clearly significative since a clinical point of view to defeat capecitabine (good, cheap, easy, per os, and with better tolerability.
Excited to share that our article on the impact of neoadjuvant #pembro in early #TNBC was just published in the @OncJournal! @jmortimer @hmcarthur Younger patients and those who completed 8 cycles of neoadjuvant pembro were more like to achieve pCR. academic.oup.com/oncolo/advance…
Please include some patients with “marker-negative” tumors in early #drugdevelopment. Drugs often have more targets than we know, & sometimes the first target we find isn’t even the best one. It’s a lot more resource-intensive to go back & figure this out. #OncTwitter
@PTarantinoMD The question is rather, how much does the specific payload subtype contribute to the efficacy vs toxicity of the typical ADC? Come to ILCC24 in Huntington Beach on July 25-27 and find out. @HwakeleeMD @DrRoyHerbstYale @gotoPER @IASLC
What is the contribution of the payload to the molecular weight of a typical ADC?
📢 Monday early morning press release notes -"The DESTINY-Breast06 -trastuzumab deruxtecan phase 3 trial has reported positive topline results" - for patients with Her2 low and ultra-low! 👉How low can you go? This morning, @ErikaHamilton9 @SarahCannonDocs enlightened us…
Really feel like we don't need to be testing for HER-2 for TDXd in #bcsm: 1) IHC testing isn't that good 2) HER-2 is so heterogeneous biopsy to biopsy 3) other ADCs we don't test (TROP, HER-3 etc). Only b/c it was "HER-2" did we get stuck in this testing algorithm to begin with!
The first randomized trial of medical #AI to show it saves lives ECG-AI alert in 16,000 hospitalized patients 31% reduction of mortality (absolute 7 per 100 patients) in pre-specified high-risk group nature.com/articles/s4159… @NatureMedicine
Seems like the gift that keeps giving! TDXD shows improvement in PFS in primary and overall population including HER2 low and HER2 ultra low HR + MBC in DESTINY-Breast06 Phase III trial. Can't wait to see the details @OncoAlert #bcsm astrazeneca.com/media-centre/p…
In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC Press release out from DESTINY-Breast06 Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker
NEWS FROM INDUSTRY Results from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan🧪could become a new standard of care for #HER2 -low 🧬and HER2-ultralow metastatic #BreastCancer patients ➡️showing significant PFS improvements 📈over standard chemotherapy after…
Well, the @DanaFarber_GU is hiring again: Apply at: nejmcareercenter.org/job/760635/gen…
I’ve told you guys before😉 You can trust-uzumab deruxtecan!
NEWS FROM INDUSTRY Results from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan🧪could become a new standard of care for #HER2 -low 🧬and HER2-ultralow metastatic #BreastCancer patients ➡️showing significant PFS improvements 📈over standard chemotherapy after…
ついに来ました！HER2-lowにおける1st lineの標準治療が変わります。DESTINY-Breast06試験: ホルモン受容体陽性HER2低発現の転移再発乳癌の1次治療において、T-DXd(エンハーツ)が従来の標準治療と比べて統計学的に有意なPFS延長を認めたとのこと。businesswire.com/news/home/2024…
⭐️When an “interim” analysis of a phase 1 trial is published in @Nature it must be extraordinary. 👉🏼Phase 1 trial of mRNA to treat an inborn error of metabolism -propionic acidemia 👉🏼This is ultimate #PrecisionMedicine & Phenomenal that two gene products were delivered to…
Trends for United States
You might like
